Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Atlab Pharma
DescriptionHumanized mAb targeting prostate-specific membrane antigen (PSMA; FOLH1; GCPII) coupled with lutetium-177
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today